keyword
MENU ▼
Read by QxMD icon Read
search

Seth Baum

keyword
https://www.readbyqxmd.com/read/27783842/the-american-society-for-preventive-cardiology-our-30-year-legacy
#1
Nathan D Wong, Laurence S Sperling, Seth J Baum
No abstract text is available yet for this article.
October 26, 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/27678440/us-physician-practices-for-diagnosing-familial-hypercholesterolemia-data-from-the-cascade-fh-registry
#2
Zahid S Ahmad, Rolf L Andersen, Lars H Andersen, Emily C O'Brien, Iris Kindt, Peter Shrader, Chandna Vasandani, Connie B Newman, Emil M deGoma, Seth J Baum, Linda C Hemphill, Lisa C Hudgins, Catherine D Ahmed, Iftikhar J Kullo, Samuel S Gidding, Danielle Duffy, William Neal, Katherine Wilemon, Matthew T Roe, Daniel J Rader, Christie M Ballantyne, MacRae F Linton, P Barton Duell, Michael D Shapiro, Patrick M Moriarty, Joshua W Knowles
BACKGROUND: In the US familial hypercholesterolemia (FH), patients are underidentified, despite an estimated prevalence of 1:200 to 1:500. Criteria to identify FH patients include Simon Broome, Dutch Lipid Clinic Network (DLCN), or Make Early Diagnosis to Prevent Early Deaths (MEDPED). The use of these criteria in US clinical practices remains unclear. OBJECTIVE: To characterize the FH diagnostic criteria applied by US lipid specialists participating in the FH Foundation's CASCADE FH (CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia) patient registry...
September 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27667377/emerging-treatments-for-heterozygous-and-homozygous-familial-hypercholesterolemia
#3
Seth J Baum, Daniel Soffer, P Barton Duell
Familial hypercholesterolemia (FH) is an autosomal co-dominant disorder marked by extremely high low-density lipoprotein (LDL) cholesterol levels and concomitant premature vascular disease. FH is caused by mutations that most commonly affect three genes integrally involved in the LDL receptor's ability to clear LDL particles from the circulation. Primary intervention efforts to lower LDL cholesterol have centered on therapies that upregulate the LDL receptor. Unfortunately, most patients are insufficiently responsive to traditional LDL-lowering medications...
2016: Reviews in Cardiovascular Medicine
https://www.readbyqxmd.com/read/27462479/focal-correction-of-severe-fixed-kyphosis-with-single-level-posterior-ponte-osteotomy-and-interbody-fusion
#4
Seth S Molloy, Faiz U Ahmad, Griffin R Baum, Barth A Green, Nathan H Lebwohl
OBJECTIVE: To report the successful correction of a severe, fixed kyphotic deformity utilizing a combination posterior lumbar interbody fusion (PLIF) and Ponte osteotomy at the site of acute kyphosis. SUMMARY OF BACKGROUND DATA: There have been no reports on the experience and surgical strategy of combined one-level focal PLIF and Ponte osteotomy for fixed severe kyphotic deformity. Typically, these corrections would need a pedicle subtraction osteotomy or a vertebrectomy...
2016: Curēus
https://www.readbyqxmd.com/read/27422124/focus-on-pcsk9-inhibitors-from-genetics-to-clinical-practice
#5
Marc S Sabatine, James A Underberg, Michael Koren, Seth J Baum
Elevation of low-density lipoprotein cholesterol (LDL-C) is an important cause of atherosclerotic cardiovascular disease (ASCVD). Over the years, clinical outcome studies with LDL-C lowering agents have revealed that reducing LCL-C levels is effective in reducing rates of major ASCVD events. Although secondary factors play a role in clinical expression, severe lipid disorders often have a strong genetic component. Genetic revelations have provided novel targets for improving LDL-C management in high-risk individuals...
October 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27246162/defining-severe-familial-hypercholesterolaemia-and-the-implications-for-clinical-management-a-consensus-statement-from-the-international-atherosclerosis-society-severe-familial-hypercholesterolemia-panel
#6
REVIEW
Raul D Santos, Samuel S Gidding, Robert A Hegele, Marina A Cuchel, Philip J Barter, Gerald F Watts, Seth J Baum, Alberico L Catapano, M John Chapman, Joep C Defesche, Emanuela Folco, Tomas Freiberger, Jacques Genest, G Kees Hovingh, Mariko Harada-Shiba, Steve E Humphries, Ann S Jackson, Pedro Mata, Patrick M Moriarty, Frederick J Raal, Khalid Al-Rasadi, Kausik K Ray, Zelijko Reiner, Eric J G Sijbrands, Shizuya Yamashita
Familial hypercholesterolaemia is common in individuals who had a myocardial infarction at a young age. As many as one in 200 people could have heterozygous familial hypercholesterolaemia, and up to one in 300 000 individuals could be homozygous. The phenotypes of heterozygous and homozygous familial hypercholesterolaemia overlap considerably; the response to treatment is also heterogeneous. In this Review, we aim to define a phenotype for severe familial hypercholesterolaemia and identify people at highest risk for cardiovascular disease, based on the concentration of LDL cholesterol in blood and individuals' responsiveness to conventional lipid-lowering treatment...
October 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/27055975/accelerated-atherosclerosis-and-elevated-lipoprotein-a-after-liver-transplantation
#7
Abdulla A Damluji, Diala El-Maouche, Ali Alsulaimi, Paul Martin, Robert D Shamburek, Ronald B Goldberg, Seth J Baum, Eduardo J de Marchena
Cumulative evidence suggests that lipoprotein(a) [Lp(a)] exerts an independent effect on the initiation and progression of atherosclerotic cardiovascular disease. The genetically mediated expression of apolipoprotein(a), which is the key structural and functional component of Lp(a), occurs in hepatocytes with subsequent extracellular Lp(a) assembly at the hepatic cell surface. Here, we describe a case of elevated Lp(a) concentrations identified after (and likely acquired by) orthotopic liver transplantation that contributed to accelerated atherosclerotic cardiovascular disease despite intensive therapeutic interventions...
March 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27013694/treatment-gaps-in-adults-with-heterozygous-familial-hypercholesterolemia-in-the-united-states-data-from-the-cascade-fh-registry
#8
Emil M deGoma, Zahid S Ahmad, Emily C O'Brien, Iris Kindt, Peter Shrader, Connie B Newman, Yashashwi Pokharel, Seth J Baum, Linda C Hemphill, Lisa C Hudgins, Catherine D Ahmed, Samuel S Gidding, Danielle Duffy, William Neal, Katherine Wilemon, Matthew T Roe, Daniel J Rader, Christie M Ballantyne, MacRae F Linton, P Barton Duell, Michael D Shapiro, Patrick M Moriarty, Joshua W Knowles
BACKGROUND: Cardiovascular disease burden and treatment patterns among patients with familial hypercholesterolemia (FH) in the United States remain poorly described. In 2013, the FH Foundation launched the Cascade Screening for Awareness and Detection (CASCADE) of FH Registry to address this knowledge gap. METHODS AND RESULTS: We conducted a cross-sectional analysis of 1295 adults with heterozygous FH enrolled in the CASCADE-FH Registry from 11 US lipid clinics...
June 2016: Circulation. Cardiovascular Genetics
https://www.readbyqxmd.com/read/26892999/statins-and-diabetes
#9
REVIEW
Kevin C Maki, Mary R Dicklin, Seth J Baum
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes. The NLA panel advocated following the standards of care from the American Diabetes Association for screening and diagnosis of diabetes, and emphasized the importance of lifestyle modification...
March 2016: Endocrinology and Metabolism Clinics of North America
https://www.readbyqxmd.com/read/26337173/insights-into-statin-intolerance
#10
Stephen Kopecky, Seth Baum, JoAnne M Foody, Michael Koren, James McKenney, Laurence Sperling, Nathan D Wong
No abstract text is available yet for this article.
September 2015: Clinical Cardiology
https://www.readbyqxmd.com/read/25939296/statins-and-diabetes
#11
REVIEW
Kevin C Maki, Mary R Dicklin, Seth J Baum
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes. The NLA panel advocated following the standards of care from the American Diabetes Association for screening and diagnosis of diabetes, and emphasized the importance of lifestyle modification...
May 2015: Cardiology Clinics
https://www.readbyqxmd.com/read/25499935/the-doctor-s-dilemma-challenges-in-the-diagnosis-and-care-of-homozygous-familial-hypercholesterolemia
#12
EDITORIAL
Seth J Baum, E J G Sijbrands, Pedro Mata, Gerald F Watts
No abstract text is available yet for this article.
November 2014: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/24142523/adherence-to-preventive-exercises-and-self-reported-swallowing-outcomes-in-post-radiation-head-and-neck-cancer-patients
#13
Eileen Huh Shinn, Karen Basen-Engquist, George Baum, Sven Steen, Rachel Freeman Bauman, William Morrison, Adam Seth Garden, Cathleen Sheil, Kelly Kilgore, Katherine A Hutcheson, Denise Barringer, Ying Yuan, Jan S Lewin
BACKGROUND: To reduce the risk of long-term swallowing complications after radiation, swallowing exercises may be helpful. Both the rate of adherence to swallowing exercises and its impact on future swallowing function are unknown. METHODS: In all, 109 patients with oropharyngeal cancer beginning radiation were tracked for 2 years to determine adherence to swallowing exercises. Participants completed the MD Anderson Dysphagia Inventory (MDADI) 1-2 years after treatment, to assess self-reported swallowing function...
December 2013: Head & Neck
https://www.readbyqxmd.com/read/23102543/a-survey-of-internists-and-cardiologists-are-discoveries-in-fatty-acids-truly-being-translated-into-clinical-practice
#14
Seth J Baum
No abstract text is available yet for this article.
January 2013: Prostaglandins, Leukotrienes, and Essential Fatty Acids
https://www.readbyqxmd.com/read/22658146/fatty-acids-in-cardiovascular-health-and-disease-a-comprehensive-update
#15
REVIEW
Seth J Baum, Penny M Kris-Etherton, Walter C Willett, Alice H Lichtenstein, Lawrence L Rudel, Kevin C Maki, Jay Whelan, Christopher E Ramsden, Robert C Block
Research dating back to the 1950s reported an association between the consumption of saturated fatty acids (SFAs) and risk of coronary heart disease. Recent epidemiological evidence, however, challenges these findings. It is well accepted that the consumption of SFAs increases low-density lipoprotein cholesterol (LDL-C), whereas carbohydrates, monounsaturated fatty acids (MUFAs), and polyunsaturated fatty acids (PUFAs) do not. High-density lipoprotein (HDL)-C increases with SFA intake. Among individuals who are insulin resistant, a low-fat, high-carbohydrate diet typically has an adverse effect on lipid profiles (in addition to decreasing HDL-C, it also increases triglyceride and LDL particle concentrations)...
May 2012: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/22528120/evidence-based-medicine-what-s-the-evidence
#16
EDITORIAL
Seth J Baum
No abstract text is available yet for this article.
May 2012: Clinical Cardiology
https://www.readbyqxmd.com/read/21516371/climate-change-evidence-of-human-causes-and-arguments-for-emissions-reduction
#17
COMMENT
Seth D Baum, Jacob D Haqq-Misra, Chris Karmosky
In a recent editorial, Raymond Spier expresses skepticism over claims that climate change is driven by human actions and that humanity should act to avoid climate change. This paper responds to this skepticism as part of a broader review of the science and ethics of climate change. While much remains uncertain about the climate, research indicates that observed temperature increases are human-driven. Although opinions vary regarding what should be done, prominent arguments against action are based on dubious factual and ethical positions...
June 2012: Science and Engineering Ethics
https://www.readbyqxmd.com/read/21258049/distinct-in-vitro-binding-properties-of-the-anti-cd20-small-modular-immunopharmaceutical-2lm20-4-result-in-profound-and-sustained-in-vivo-potency-in-cynomolgus-monkeys
#18
COMPARATIVE STUDY
Cheryl Nickerson-Nutter, Lioudmila Tchistiakova, Nilufer P Seth, Marion Kasaian, Barbara Sibley, Stephane Olland, Richard Zollner, William A Brady, Kendall M Mohler, Peter Baum, Alan Wahl, Deborah Herber, Yulia Vugmeyster, David Wensel, Neil M Wolfman, Davinder Gill, Mary Collins, Kyri Dunussi-Joannopoulos
OBJECTIVES: To characterize the in vitro binding and effector function properties of CD20-directed small modular immunopharmaceutical (SMIP) 2LM20-4, and to compare its in vivo B-cell depletion activity with the mutated 2LM20-4 P331S [no in vitro complement-dependent cytotoxicity (CDC)] and rituximab in cynomolgus monkeys. METHODS: Direct binding is examined in flow cytometry, confocal microscopy, scatchard and lipid raft assays. Effector function assays include CDC and Fc-mediated cellular toxicity...
June 2011: Rheumatology
https://www.readbyqxmd.com/read/20532667/intrinsic-ethics-regarding-integrated-assessment-models-for-climate-management
#19
Erich W Schienke, Seth D Baum, Nancy Tuana, Kenneth J Davis, Klaus Keller
In this essay we develop and argue for the adoption of a more comprehensive model of research ethics than is included within current conceptions of responsible conduct of research (RCR). We argue that our model, which we label the ethical dimensions of scientific research (EDSR), is a more comprehensive approach to encouraging ethically responsible scientific research compared to the currently typically adopted approach in RCR training. This essay focuses on developing a pedagogical approach that enables scientists to better understand and appreciate one important component of this model, what we call intrinsic ethics...
September 2011: Science and Engineering Ethics
https://www.readbyqxmd.com/read/19407042/grim-news-for-an-unoriginal-position-a-reply-to-seth-baum
#20
COMMENT
D Benatar
Seth Baum suggests that my claim that it is better never to come into existence "can readily be rejected not just out of reflexive distaste for the claim but also out of sound ethical reasoning". In my reply, I argue that Mr Baum fails to state accurately what my arguments are, and then attempts to refute them by association with other views that he dismisses perfunctorily. Where he does actually engage in my views, his response is effectively merely to assert the opposite.
May 2009: Journal of Medical Ethics
keyword
keyword
95648
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"